Tesmilifene (original) (raw)
Tesmilifene (INN; developmental code names YMB-1002, BMS-217380-01), also known as N,N-diethyl-2-(4-phenylmethyl)ethanamine (DPPE), is a small-molecule antineoplastic drug and chemopotentiator that was under development by YM BioSciences for the treatment of breast cancer in the 2000s but was never marketed. It reached phase III clinical trials for advanced/metastatic breast cancer before development was discontinued.
| Property | Value |
|---|---|
| dbo:abstract | Tesmilifene (INN; developmental code names YMB-1002, BMS-217380-01), also known as N,N-diethyl-2-(4-phenylmethyl)ethanamine (DPPE), is a small-molecule antineoplastic drug and chemopotentiator that was under development by YM BioSciences for the treatment of breast cancer in the 2000s but was never marketed. It reached phase III clinical trials for advanced/metastatic breast cancer before development was discontinued. Tesmilifene is a diphenylmethane derivative that is structurally related to the triphenylethylene derivative tamoxifen but lacks the stilbene bridge and third phenyl ring necessary for binding to the estrogen receptor (ER), and as such, it is not a selective estrogen receptor modulator (SERM). In addition to tamoxifen, tesmilifene is structurally related to diphenylmethane antihistamines like diphenhydramine and hydroxyzine, but is much weaker than these agents in assays of anti-H1 receptor activity, and hence, neither acts as an antihistamine. Tamoxifen is known to bind not only to the ER but also to non-ER so-called "antiestrogen binding sites" (AEBS) that are present in cell microsomes as opposed to the cell nucleus. Tesmilifene was developed as a selective ligand of the AEBS without ER affinity to investigate these sites and their role in the antineoplastic activity of tamoxifen. Histamine has been found to be a ligand of the AEBS, and it has been determined that the AEBS represent the substrate binding site of certain microsomal cytochrome P450 enzymes including CYP3A4, CYP2D6, and CYP1A1. Tesmilifene binds to and displaces histamine from these sites equipotently to tamoxifen and more strongly than conventional antihistamines, and this action has been found to correlate with the cytotoxic effects of tesmilifene in breast cancer cells in vitro. Moreover, in spite of its lack of affinity for the ER, tesmilifene antagonizes the uterotrophic effects of exogenous estrogen in vivo. (en) |
| dbo:casNumber | 92981-78-7 (hydrochloride) 98774-23-3 |
| dbo:chEBI | 93414 |
| dbo:chEMBL | 26424 |
| dbo:fdaUniiCode | I43T3ID6G2 |
| dbo:pubchem | 108092 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Tesmilifene.svg?width=300 |
| dbo:wikiPageExternalLink | http://adisinsight.springer.com/drugs/800005041 |
| dbo:wikiPageID | 53753696 (xsd:integer) |
| dbo:wikiPageLength | 5693 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1072756645 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Bridged_compounds dbr:Breast_cancer dbr:Hydroxyzine dbr:Cytochrome_P450 dbr:In_vitro dbr:In_vivo dbr:Ligand_(biochemistry) dbc:Abandoned_drugs dbr:Estrogen dbr:Enzyme dbr:Phenyl_ring dbr:Antihistamine dbr:Clinical_trial dbr:Receptor_antagonist dbr:Substrate_(biochemistry) dbr:Microsome dbr:Cell_(biology) dbr:Triphenylethylene dbr:Cytotoxic dbr:Estrogen_receptor dbr:Cell_nucleus dbc:Antineoplastic_drugs dbc:Diethylamino_compounds dbr:Histamine dbr:International_Nonproprietary_Name dbr:Tamoxifen dbr:Hydrochloride dbr:Chemotherapy dbr:Affinity_(pharmacology) dbr:Binding_site dbr:Bioassay dbr:Diphenhydramine dbr:Diphenylmethane dbr:CYP1A1 dbr:CYP2D6 dbr:CYP3A4 dbr:Exogenous dbr:H1_receptor dbr:Metastatic_breast_cancer dbr:Selective_estrogen_receptor_modulator dbr:Phases_of_clinical_research dbr:Sivifene dbr:Stilbene dbr:Chemical_derivative dbr:Small-molecule dbr:Uterotrophic dbr:Antineoplastic_drug dbr:YM_BioSciences |
| dbp:c | 19 (xsd:integer) |
| dbp:casNumber | 98774 (xsd:integer) |
| dbp:casSupplemental | 92981 (xsd:integer) |
| dbp:chebi | 93414 (xsd:integer) |
| dbp:chembl | 26424 (xsd:integer) |
| dbp:chemspiderid | 97190 (xsd:integer) |
| dbp:h | 25 (xsd:integer) |
| dbp:iupacName | 2 (xsd:integer) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pubchem | 108092 (xsd:integer) |
| dbp:smiles | CCNCCOC1=CC=CCC2=CC=CC=C2 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | NFIXBCVWIPOYCD-UHFFFAOYSA-N (en) |
| dbp:synonyms | BMS-217380-01; YMB-1002; DPPE (en) |
| dbp:unii | I43T3ID6G2 (en) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Reflist |
| dcterms:subject | dbc:Abandoned_drugs dbc:Antineoplastic_drugs dbc:Diethylamino_compounds |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Tesmilifene (INN; developmental code names YMB-1002, BMS-217380-01), also known as N,N-diethyl-2-(4-phenylmethyl)ethanamine (DPPE), is a small-molecule antineoplastic drug and chemopotentiator that was under development by YM BioSciences for the treatment of breast cancer in the 2000s but was never marketed. It reached phase III clinical trials for advanced/metastatic breast cancer before development was discontinued. (en) |
| rdfs:label | Tesmilifene (en) |
| owl:sameAs | yago-res:Tesmilifene wikidata:Tesmilifene https://global.dbpedia.org/id/2XtjD |
| prov:wasDerivedFrom | wikipedia-en:Tesmilifene?oldid=1072756645&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Tesmilifene.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Tesmilifene |
| is dbo:wikiPageRedirects of | dbr:BMS-217380-01 dbr:BMS_217380-01 dbr:N,N-DPPE dbr:YMB-1002 dbr:YMB1002 dbr:YMB_1002 |
| is dbo:wikiPageWikiLink of | dbr:C19H25NO dbr:List_of_selective_estrogen_receptor_modulators dbr:Sivifene dbr:BMS-217380-01 dbr:BMS_217380-01 dbr:N,N-DPPE dbr:YMB-1002 dbr:YMB1002 dbr:YMB_1002 |
| is foaf:primaryTopic of | wikipedia-en:Tesmilifene |
